class V glucose-6-phosphate dehydrogenase deficiency

Summary

class V glucose-6-phosphate dehydrogenase deficiency (MONDO:0040671) is a disease and 21 clinical trials. Top therapeutic interventions include primaquine, chloroquine, and tafenoquine. A subtype of G6PD deficiency — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 21

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	class V glucose-6-phosphate dehydrogenase deficiency
Mondo ID	MONDO:0040671
Orphanet	362
SNOMED CT	80963002
UMLS	C0272060
MedGen	543772
GARD	0027958
Is cancer (heuristic)	no

Also known as: G6PD class V variant anaemia · G6PD class V variant anemia · G6PD deficiency · glucose-6-phosphate dehydrogenase deficiency class V variant anaemia · glucose-6-phosphate dehydrogenase deficiency class V variant anemia

Disease family

This is a subtype of G6PD deficiency. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › inborn errors of metabolism › inborn carbohydrate metabolic disorder › G6PD deficiency › class V glucose-6-phosphate dehydrogenase deficiency

Related subtypes (2): favism, anemia, nonspherocytic hemolytic, due to G6PD deficiency

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 21.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	14
PHASE4	4
PHASE2	1
EARLY_PHASE1	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07468513	PHASE4	RECRUITING	Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases.
NCT02434952	PHASE4	COMPLETED	Safety and Tolerability of Low Dose Primaquine
NCT03337152	PHASE4	TERMINATED	Assessing a Risk Model for G6PD Deficiency
NCT04088513	PHASE4	UNKNOWN	Safety and Efficacy of Aspirin in Stroke Patients With Glucose-6-phosphate Dehydrogenase Deficiency (SAST)
NCT03529396	PHASE2	COMPLETED	Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in G6PD Deficient Patients
NCT04073953	PHASE1	COMPLETED	Primaquine Enantiomers in G6PD Deficient Human Volunteers
NCT02937376	EARLY_PHASE1	UNKNOWN	Effects of N-acetyl Cystein (NAC) Supplementation in G6PD Deficient Individuals After Acute Exercise
NCT03655223	Not specified	ENROLLING_BY_INVITATION	Early Check: Expanded Screening in Newborns
NCT01931644	Not specified	COMPLETED	At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
NCT02937363	Not specified	COMPLETED	Effects of Alpha Lipoic Acid Supplementation in G6PD Deficient Individuals After Acute Exercise
NCT04010695	Not specified	COMPLETED	Validation of Diagnostics to Identify Glucose-6-phosphate Dehydrogenase Activity in the US
NCT04033640	Not specified	COMPLETED	Evaluation of a Diagnostic to Identify Glucose-6-phosphate Dehydrogenase (G6PD) Deficiency in Brazil
NCT04054661	Not specified	COMPLETED	Validation of a Diagnostic Test for Glucose-6-phosphate Dehydrogenase (G6PD) Deficiency in Anti-coagulated Blood
NCT04081272	Not specified	COMPLETED	Effect of G6PD Deficiency on Red Blood Cell Storage
NCT04146246	Not specified	COMPLETED	Comparative Evaluation of the FINDER Instrument and FINDER G6PD Cartridge in Adults and Neonates
NCT05026489	Not specified	UNKNOWN	G6PD Deficiency in Infarction Patients in Shaanxi Province
NCT05096702	Not specified	UNKNOWN	Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil
NCT05571748	Not specified	UNKNOWN	Oxidative Stress, Carbohydrate Metabolism Disorders and G6PD Deficiency
NCT05753150	Not specified	COMPLETED	Operational Feasibility of Appropriate Plasmodium Vivax Radical Cure After G6PD Testing in Thailand
NCT05874271	Not specified	COMPLETED	Short Course Primaquine for the Radical Cure of P. Vivax - Papua New Guinea
NCT05879224	Not specified	COMPLETED	Short Course Primaquine for the Radical Cure of P. Vivax Malaria - Indonesia

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PRIMAQUINE	4	15
CHLOROQUINE	4	2
TAFENOQUINE	4	2
CYSTEINE	4	1
SODIUM CHROMATE CR 51	4	1
LIPOIC ACID, ALPHA	3	2